Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Truvada Growth Driven By Placement On First-Line Regimens, Gilead Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Truvada (emtricitabine/tenofovir disoproxil) brand awareness is close to 100% among HIV treatment community partly due to direct-to-consumer ads, which will continue throughout 2005, Gilead says. Most growth comes from treatment-naive patients, followed by Viread and Emtriva switches, firm says.

You may also be interested in...



Bristol/Gilead Triple Combination HIV Therapy Has Back-Up

Bristol-Myers Squibb and Gilead are developing a "back-up" formulation of the fixed-dose combination of Sustiva and Truvada that is the subject of their joint venture

GSK, Gilead HIV Fixed-Dose Combination Drugs Clear FDA

The approvals of Gilead’s Truvada and GSK’s Epzicom were announced publicly by FDA Acting Commissioner Crawford during a Washington, D.C. luncheon speech. Gilead is shipping Truvada to wholesalers this week. Two month supplies of Epzicom will be available free to patients through participating physicians for a limited time.

MorphoSys, After Its Commercial Debut, Looks To The Next Growth Phase

Interview: CEO Jean-Paul Kress talked to Scrip about the US launch of Monjuvi, commercial expansion and the aspiration to build a European biotech that can compete in the big leagues.

Topics

UsernamePublicRestriction

Register

PS062038

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel